|
End-of-day quote
Amman S.E.
20/08/2026
|
5-day change | 1st Jan Change | ||
| 1.840 JOD | -7.07% |
|
-7.07% | +15.00% |
| 07-21 | Philadelphia Pharmaceuticals Company Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-27 | Philadelphia Pharmaceuticals Q1 profit 255,632 dinars | RE |
| Market Cap | 13.8M 19.48M 16.68M 15.61M 14.29M 26.82M 1.86B 27.17M 184M 71.93M 936M 73.14M 71.55M 3.1B | P/E 2024 |
13.7x | P/E 2025 | 11.9x |
|---|---|---|---|---|---|
| Enterprise Value | 13.73M 19.38M 16.6M 15.53M 14.22M 26.69M 1.85B 27.04M 184M 71.57M 932M 72.78M 71.19M 3.08B | EV / Sales 2024 |
1.32x | EV / Sales 2025 | 1.3x |
| Free-Float |
7.27% | Yield 2024 |
4.67% | Yield 2025 | - |
| 1 day | -7.07% | ||
| 1 week | -7.07% | ||
| Current month | -8.00% | ||
| 1 month | -8.00% | ||
| 3 months | +6.98% | ||
| 6 months | +18.71% | ||
| Current year | +15.00% |
| 1 week | 1.84 | 1.87 | |
| 1 month | 1.84 | 2.01 | |
| Current year | 1.5 | 2.01 | |
| 1 year | 1.48 | 2.01 | |
| 3 years | 1.36 | 2.01 | |
| 5 years | 1.28 | 2.01 | |
| 10 years | 1.28 | 3.19 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ashraf Hussein
CEO | Chief Executive Officer | 44 | 31/12/2012 |
Rima Shanoudeh
CTO | Chief Tech/Sci/R&D Officer | - | - |
Belal Salameh
DFI | Director of Finance/CFO | 50 | 31/12/2001 |
| Director | Title | Age | Since |
|---|---|---|---|
Munther Hussein
CHM | Chairman | 58 | - |
| Director/Board Member | 61 | 31/08/2016 | |
| Director/Board Member | 64 | 31/12/2012 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -7.07% | -7.07% | +26.03% | +29.58% | 19.48M | ||
| -0.08% | -1.43% | +15.87% | +67.24% | 47.71B | ||
| -3.21% | +1.37% | +51.19% | +124.26% | 40.3B | ||
| -0.40% | -1.23% | -10.08% | +17.30% | 12.09B | ||
| +1.11% | -1.34% | +13.27% | +72.07% | 11.68B | ||
| +0.19% | +0.58% | +30.98% | +151.21% | 9.19B | ||
| -0.39% | -0.92% | +20.49% | +39.85% | 7.57B | ||
| -1.35% | +0.74% | +47.38% | -12.13% | 7.24B | ||
| -0.64% | -0.02% | +19.65% | +205.39% | 6.84B | ||
| -5.36% | -6.36% | -38.04% | +19.49% | 5.42B | ||
| Average | -1.72% | -1.80% | +17.67% | +71.42% | 14.81B | |
| Weighted average by Cap. | -1.15% | -0.57% | +24.08% | +83.62% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 8.76M 12.37M 10.59M 9.91M 9.07M 17.03M 1.18B 17.25M 117M 45.67M 594M 46.44M 45.43M 1.97B | 9.17M 12.94M 11.09M 10.37M 9.49M 17.82M 1.24B 18.05M 123M 47.79M 622M 48.59M 47.54M 2.06B |
| Net income | 822K 1.16M 993K 929K 851K 1.6M 111M 1.62M 10.98M 4.28M 55.73M 4.35M 4.26M 184M | 1.01M 1.42M 1.22M 1.14M 1.04M 1.95M 136M 1.98M 13.43M 5.24M 68.19M 5.33M 5.21M 226M |
| Net Debt | 334K 471K 403K 377K 345K 648K 45.05M 657K 4.46M 1.74M 22.63M 1.77M 1.73M 74.86M | -67.69K -95.53K -81.83K -76.57K -70.09K -132K -9.14M -133K -905K -353K -4.59M -359K -351K -15.19M |
Employees
129
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
- Stock Market
- Stocks
- PHIL Stock
Select your edition
All financial news and data tailored to specific country editions
















